| 我国创新药品医保支付改革的进展及思考 |
| |
| 引用本文： | 王海银,丛鹂萱,谢春艳,王美凤,刘昕,金春林. 我国创新药品医保支付改革的进展及思考[J]. 卫生经济研究, 2021, 0(1): 47-49 |
| |
| 作者姓名： | 王海银 丛鹂萱 谢春艳 王美凤 刘昕 金春林 |
| |
| 作者单位： | 上海市卫生和健康发展研究中心 |
| |
| 基金项目： | 上海市第四轮公共卫生三年行动计划重点学科建设项目“循证公共卫生与卫生经济学”(15GWZK0901)。 |
| |
| 摘 要： | 创新药品给患者带来了更多的健康获益,但部分创新药品价格高昂,患者自付负担较重.医保支付通过目录准入、支付方式、结算框架等方面,影响创新药品的可及性.本文归纳了我国当前创新药品医保支付改革的实践进展,提出思考建议:探索分类评价准则,完善创新药品谈判机制;探索引入条件准人协议,重视真实世界数据证据;充分整合慈善基金,完善创...
|
| 关 键 词： | 创新药品 医保支付 谈判准入 可及性 |
Progress and Consideration on the Medical Insurance Payment Reform for Innovative Drugs in China |
| |
| WANG Hai-yin,CONG Li-xuan,XIE Chun-yan,WANG Mei-feng,LIU Xin,JIN Chun-lin. Progress and Consideration on the Medical Insurance Payment Reform for Innovative Drugs in China[J]. Health Economics Research, 2021, 0(1): 47-49 |
| |
| Authors: | WANG Hai-yin CONG Li-xuan XIE Chun-yan WANG Mei-feng LIU Xin JIN Chun-lin |
| |
| Affiliation: | (Shanghai Health Development Research Center,Shanghai 200032,China;不详) |
| |
| Abstract: | Innovative drugs can bring more health benefit to patients,but some of them are expensive and patient have a heavy burden by paying cash.Insurance payment affects the accessibility of innovative drugs through the catalogue access,payment,settlement framework and so on.This paper summarizes the practical progress of current innovative drug health insurance payment reform,and puts forward some suggestions:explore the classified evaluation criteria,improve the innovative drug negotiation mechanism;explore the agreement of conditional access agreements,pay attention to real-world data evidence;fully integrate charitable funds,improve the innovative drug safety net relief mechanism;encourage commercial insurance to participate,support market behaviors such as DTP payment,and improve the accessibility of innovative drugs. |
| |
| Keywords: | innovative drugs insurance payment negotiation access accessibility |
| 本文献已被 维普 等数据库收录！ |
|
